Abstract | BACKGROUND: CASE: A 25-year-old HLA-B27-positive Japanese man presented with recurrent anterior uveitis OU. The symptoms were consistent with typical HLA-B27-associated uveitis, whereas the subsequent course, which consisted of frequent episodes of recurrent severe anterior uveitis, was atypical. Although the patient was treated with intensive topical corticosteroids, cycloplegic treatment, sub-Tenon triamcinolone acetonide injections, systemic corticosteroids and immunosuppressive agents, recurrence of the anterior uveitis persisted. Over 8 years there were 14 documented episodes of recurrent anterior uveitis OD and 10 OSs. At age 33, the patient was diagnosed with AS after a radiographic examination. We began infusions of infliximab (2.5 mg/kg) at 0, 2 and 6 weeks, and then every 8 weeks thereafter. The recurrent uveitis disappeared, and the immunosuppressive agents and oral corticosteroids were tapered and discontinued without relapse. All drugs other than infliximab were successfully stopped in October 2010. During the follow-up period, there were no adverse events. CONCLUSION:
|
Authors | Junko Matsuda, Toshikatsu Kaburaki, Shigeto Kobayashi, Jiro Numaga |
Journal | Japanese journal of ophthalmology
(Jpn J Ophthalmol)
Vol. 57
Issue 1
Pg. 104-7
(Jan 2013)
ISSN: 1613-2246 [Electronic] Japan |
PMID | 23108527
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Antibodies, Monoclonal
- HLA-B27 Antigen
- Tumor Necrosis Factor-alpha
- Infliximab
|
Topics |
- Adult
- Anti-Inflammatory Agents, Non-Steroidal
(administration & dosage)
- Antibodies, Monoclonal
(administration & dosage)
- Chronic Disease
- Dose-Response Relationship, Drug
- HLA-B27 Antigen
(blood, immunology)
- Humans
- Infliximab
- Infusions, Intravenous
- Male
- Recurrence
- Spondylitis, Ankylosing
(complications, drug therapy, immunology)
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
- Uveitis, Anterior
(complications, drug therapy, immunology)
|